ABSTRACT OBJECTIVES This study sought to determine whether severe right ventricular (RV) dysfunction in the pre-operative setting is associated with an increased risk of gastrointestinal bleeding (GIB) post-left ventricular assist device (LVAD).
Complications of durable mechanical circulatory support including bleeding, infection, and thrombotic events are significant sources of morbidity in this population (1, 4, 7, 10, 11) . Gastrointestinal bleeding (GIB) represents the most common complication of support with CF-LVADs, occurring in 20% to 40% of patients with an incidence of 0.2 to 0.6 events per patient year (2, (11) (12) (13) (14) (15) (16) . GIB is associated with hospital readmissions and invasive procedures resulting in significant resource utilization and decreased quality of life (15) (16) (17) . Additionally, bleeding events typically lead to interruptions in antithrombotic therapy, which may increase thrombotic complications (15, 16, 18, 19) . Moreover, GIB events frequently necessitate blood transfusions, potentially increasing the chance of allosensitization (20) . This is particularly problematic in BTT patients in whom the prevalence of sensitization has increased markedly in the CF-LVAD era (20) .
Several mechanisms have been implicated in the increased incidence of GIB after implantation of CFLVADs. The requirement for antithrombotic therapy has increased the incidence of GIB compared to pulsatile-flow LVADs, but bleeding rates far exceed those of other populations requiring anticoagulation (12, (21) (22) (23) . Acquired von-Willebrand factor deficiency has been shown consistently after LVAD implantation, suggesting a role for impaired platelet aggregation (14, (24) (25) (26) (27) (28) (29) (30) . Continuous blood flow and elevated central venous pressure (CVP) have been theorized to increase intraluminal pressure and mucosal ischemia, resulting in a gastrointestinal milieu conducive to angiodysplasia formation (26, (31) (32) (33) (34) . Supporting this theory, low pulsatility index (PI) and persistent aortic valve closure were associated with bleeding in patients supported with the HeartMate II (Thoratec Corp., Pleasanton, California) in a recent study (35) .
Although our understanding of mechanisms promoting bleeding has improved, predicting which patients may be at increased risk has proven challenging.
Pre-operative risk factors consistently associated with GIB include older age and a history of GIB (14) (15) (16) 36) . Other factors including female sex and ischemic cardiomyopathy have been implicated as risk factors, but these findings have yet to be validated in larger patient cohorts (14, 36) . The lack of consistent data has precluded development of a pre-operative risk model to identify patients at increased risk of GIB. Right ventricular (RV) dysfunction is associated with poor post-operative outcomes resulting from hepatic congestion, coagulopathy, and diminished cardiac output characterized by low pulsatility and elevated CVP (37, 38) . Given the theoretical links of these sequelae to bleeding, we hypothesized that assessment of pre-operative RV dysfunction might identify patients at increased risk of post-operative GIB. To address this hypothesis we evaluated the impact of severe pre-operative RV dysfunction on the risk of GIB in patients supported with CF-LVADs. 
Sparrow et al. A secondary analysis was also performed to identify independent predictors of GIB risk. Statistical methods were performed as outlined for the primary analysis above. A 2-sided p value of <0.05 was considered significant. All data analysis was conducted in SAS version 9.4 (SAS Institute Inc., Cary, North Carolina).
RESULTS
PATIENT CHARACTERISTICS. The majority of patients in both groups were male (79%) with a median INTERMACS profile of 2 at the time of LVAD implantation ( Table 1) . Most patients were supported with a HeartMate II in both the severe RV dysfunction and control cohort (92% vs. 86%; p ¼ 0.43). There were no significant differences between cohorts with respect to demographics including age, race, or body mass index. In both groups, 54% of patients were deemed to have ICM, and there were no differences in other relevant comorbidities ( Table 1) .
Laboratory data revealed no differences between groups with respect to post-operative renal and hepatic function ( Table 1) . Antithrombotic therapy instituted perioperatively resulted in similar Invasive hemodynamic measurements also showed a trend toward higher RA pressure in the group with severe RV dysfunction. RV end diastolic diameter was increased in the RV dysfunction group when compared to the control group, and there was also a trend toward more severe tricuspid regurgitation in these patients ( Table 2) . Table 1) . Use of bosentan was not associated with an increased risk of GIB ( Table 3 ). Concurrent tricuspid valve repair was performed in a total of 14 patients (6.6%; 7.4% of controls vs. Table 4) .
Among patients who reached the primary outcome, there were no statistically significant differences between cohorts in INR, platelet count, or aspirin dosing at the time of admission for GIB ( Table 5) . Multiple GIB events were observed in 35.1% of patients with RV dysfunction compared to 17.1% of controls. There were no differences in location or source of GIB between groups, or in diagnostic procedure utilized to identify bleeding (Online Figures 1 and 2 , Online Appendix).
SECONDARY OUTCOMES. Excluding mortality within 30 days of implantation, there were no mortality differences during the total study follow-up period between patients with severe RV dysfunction and controls. There were nonsignificant trends toward increased epistaxis and hemolysis among the severe RV dysfunction cohort ( Table 6 ).
VALIDATION ANALYSES. Although our analysis was initially geared to identify pre-operative factors associated with GIB, we sought to further validate our findings by assessing the association between postoperative parameters of RV dysfunction and the risk of GIB. We chose not to use echocardiographic parameters for this analysis as post-operative TTE is limited by poor image quality, inconsistent timing of study performance, variation of pump speeds, and loss of TAPSE signal (Online Table 1 ).
Elevated CVP is associated with RV dysfunction and was shown to be a pre-operative predictor of GIB.
Patients were stratified by terciles according to postoperative CVP measured at 48 to 72 h after device implantation. After mean follow-up of 12 months, there was a significant association between higher CVP and bleeding ( Figure 3A) .
Post-operative RV dysfunction is frequently associated with the need for prolonged inotrope support ($ 14 days) after LVAD implantation. Therefore, in an expanded cohort, we also assessed GIB risk based on whether prolonged inotrope support was necessary.
Using a cut-off of 14 days, patients requiring prolonged inotrope use were at increased risk of subsequent GIB ( Figure 3B ).
To further assess the link between RV function and GIB, we compared clinical and RV function parameters in patients who had a GIB versus those who did not. RA pressure was significantly higher in patients with GIB with a strong trend towards significance for reduced TAPSE and increased right ventricular enddiastolic diameter (RVEDD), supporting a link between RV dysfunction and GIB. Persistent aortic valve (AV) closure on echocardiogram and PI did not differ between bleeders and nonbleeders. In addition to RV dysfunction parameters, patients with GIB tended to be older and were implanted with a DT strategy. A history of smoking and chronic obstructive pulmonary disorder (COPD) also trended towards significance in patients with GIB, perhaps related to negative effects of pulmonary disease on RV function ( Table 3) .
DISCUSSION
GIB remains a significant cause of morbidity in patients with CF-LVADs. Although our understanding of the mechanisms underlying this complication has improved, the identification of risk predictors for GIB events has proven difficult. Only older age and history of bleeding have been consistently implicated as pre-operative risk factors (14) (15) (16) 36) . Acquired von Willebrand factor deficiency has been described in all patients with CF-LVADs and likely reflects shearing of von Willebrand factor multimers (14, (24) (25) (26) (27) (28) (29) (30) . Antithrombotic therapy also has a role in the increased bleeding risk compared to previous generations of LVADs (11, 12, 21) . Given that these factors affect all CF-LVAD patients, we sought to determine additional factors that could be identified pre-operatively that predict an individual's risk of bleeding. GIB in LVAD patients has been partly attributed to angiodysplasias, which account for 30% to 40% of GIB events in these patients (24, 26, 32, 33) . Low pulsatility and venous hypertension have been implicated in the development of angiodysplasias (12, 26, 40, 41) . RV dysfunction is associated with hepatic congestion, coagulopathy, elevated CVP, and low pulsatility. Therefore, we hypothesized that pre-operative RV dysfunction would identify patients with an increased risk of GIB after LVAD (37, 38, 42) . Consistent with our hypothesis, our analysis revealed a significant association between severe RV dysfunction and GIB in patients supported with CF-LVADs.
In this study we did not pre-specify criteria for the definition of severe RV dysfunction, and instead used the assessment of expert echocardiographers who interpreted the images independent of this study.
However, retrospective analysis of the echocardiograms confirmed that the patient cohorts were well separated with regard to objective parameters of RV function including TAPSE, RV Tei, and RVEDD. We observed a modest increase in the duration of postoperative inotropes; however, the need for right ventricular assist devices was not different between the cohorts. This is likely explained by our decision to exclude patients who died in the perioperative period and our institutional practice of not implanting LVADs into patients with clinical RV failure. Accordingly, this data set provided us with a unique opportunity to Abbreviations as in Tables 1 and 3 . Values are mean AE SD or n (%). *Values taken from admission labs on admission for GIB event.
Abbreviations as in Table 1 . LDH ¼ lactate dehydrogenase; other abbreviations as in Table 1 .
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CONCLUSIONS
GIB remains a significant complication of CF-LVAD therapy. Currently, the ability to predict the risk of bleeding in patients before device implantation is limited. In this study we provide evidence that TRANSLATIONAL OUTLOOK: This study represents an initial step in the development of a risk score that could predict bleeding complications after LVAD implantation.
